Nav: Home

Connecting the dots between insulin resistance, unhealthy blood vessels and cancer

May 01, 2017

BOSTON - (May 1, 2017) - Over the decades, scientists have repeatedly shown that patients with increased levels of the hormone insulin in their blood can experience increased risks of cancer. Surprisingly, however, Joslin Diabetes Center researchers now have discovered that impaired effects of insulin also can boost these risks.

The Joslin team found that intestinal tumors grow just as quickly in a mouse cancer model whose "epithelial" cells lining the inside of the intestine have been genetically modified so that insulin can't activate the cells. A second surprise came when the investigators discovered that such tumors grow more quickly in mice when cells in blood vessels surrounding the intestine were genetically modified in the same way.

The research highlights biological mechanisms driven by insulin resistance that impair blood vessel health and may be shared by both cancer and cardiovascular disease, says Christian Rask-Madsen, M.D., Ph.D., a Joslin assistant investigator, an assistant professor at Harvard Medical School and corresponding author on a paper describing the work in the journal Oncogene.

The study was a collaboration between the labs of Rask-Madsen and C. Ronald Kahn, Joslin's chief academic officer. Years ago, the Kahn lab pioneered techniques to genetically modify given cell types to "knock out" the insulin receptor protein on the cell surface, which activates insulin's actions in the cell, thus creating a state of insulin resistance just in these cells.

In a first set of experiments, postdoctoral researcher and co-lead author Max-Felix Häring found that insulin increased the proliferation of mouse epithelial tumor cells in culture, as expected. But when he and his co-workers created mice modified to carry such cells lacking an insulin receptor, the tumors grew at the same rates as in mice with normal epithelial tumor cells.

That paradox raised questions about the role of insulin signaling among other cells in the tumor microenvironment that surrounds the cancer cells, says Rask-Madsen. So Xuanchun Wang, a postdoctoral researcher and co-lead author on the paper, followed up by generating mice lacking the insulin receptor in "vascular endothelial" cells (which line blood vessels).

Knowing that insulin can stimulate the growth of blood vessels, "our expectation was that knocking out insulin signaling in these cells might slow the growth of blood vessels and reduce tumor formation in these mice," Rask-Madsen says. "But we saw the opposite--an increase in tumor formation."

In earlier work as a postdoctoral researcher in the lab of George King, M.D., Joslin's chief scientific officer, Rask-Madsen studied the links between insulin resistance and arterial disease. This research helped to show that insulin resistance in vascular endothelial cells can create a pro-inflammatory state marked by the heightened presence of certain cell adhesion proteins that make immune cells stick to endothelial cells, the first step in enabling the immune cells to travel from the blood stream to tissues.

Now applying the concept to tumor formation, Rask-Madsen and his colleagues discovered similar signs of a pro-inflammatory state in the mice with insulin receptors knocked-out in vascular endothelial cells. These mice displayed higher levels of both cell-adhesion proteins and of immune cells called neutrophils. This would be expected to promote tumor progression and could therefore explain the increase in tumors in these mice.

"We're very interested in following up by finding more direct proof that if you block the recruitment of immune cells to tumors, you can reverse this phenomenon in these animals with endothelial cell insulin resistance," Rask-Madsen says. Additionally, his team will examine indications that the same pathways may be at work in people.

Although scientists have examined insulin action in tumors for years, the ability to knock out the insulin receptor in specific types of tumor cells adds a level of sophistication to these investigations, Rask-Madsen emphasizes. "It's also important to look not only at different tumor cell transformations but at all the cells in the tumor microenvironment, including these endothelial cells," he says.

"We have a real opportunity to propose mechanisms for the risk factors that overlap for cardiovascular disease and cancer formation," he adds. "We're very interested to see if modifying these risk factors could improve vascular function and reduce risk of both cancer and cardiovascular disease."
-end-
Lead funding for the research came from the National Cancer Institute. Other Joslin co-authors included Samuel Lockhart, Ditte Sørensen and Siegfried Ussar. Thomas Rathjen of Novo Nordisk contributed while participating in a joint fellowship between Joslin and the company. Other co-authors included Lars Melholt Rasmussen of the Odense University Hospital and the University of Southern Denmark in Odense, Denmark, and Monica Bertagnolli of Brigham and Women's Hospital in Boston and Harvard Medical School.

About Joslin Diabetes Center

Joslin Diabetes Center is world-renowned for its deep expertise in diabetes treatment and research. Joslin is dedicated to finding a cure for diabetes and ensuring that people with diabetes live long, healthy lives. We develop and disseminate innovative patient therapies and scientific discoveries throughout the world. Joslin is an independent, non-profit institution affiliated with Harvard Medical School, and one of only 11 NIH-designated Diabetes Research Centers in the U.S.

For more information, visit http://www.joslin.org or follow @joslindiabetes

Joslin Diabetes Center

Related Cancer Articles:

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.
Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.
Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.
Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.
More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.
New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.
American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.
Oncotarget: Cancer pioneer employs physics to approach cancer in last research article
In the cover article of Tuesday's issue of Oncotarget, James Frost, MD, PhD, Kenneth Pienta, MD, and the late Donald Coffey, Ph.D., use a theory of physical and biophysical symmetry to derive a new conceptualization of cancer.
Health indicators for newborns of breast cancer survivors may vary by cancer type
In a study published in the International Journal of Cancer, researchers from the UNC Lineberger Comprehensive Cancer Center analyzed health indicators for children born to young breast cancer survivors in North Carolina.
Few women with history of breast cancer and ovarian cancer take a recommended genetic test
More than 80 percent of women living with a history of breast or ovarian cancer at high-risk of having a gene mutation have never taken the test that can detect it.
More Cancer News and Cancer Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Uncharted
There's so much we've yet to explore–from outer space to the deep ocean to our own brains. This hour, Manoush goes on a journey through those uncharted places, led by TED Science Curator David Biello.
Now Playing: Science for the People

#555 Coronavirus
It's everywhere, and it felt disingenuous for us here at Science for the People to avoid it, so here is our episode on Coronavirus. It's ok to give this one a skip if this isn't what you want to listen to right now. Check out the links below for other great podcasts mentioned in the intro. Host Rachelle Saunders gets us up to date on what the Coronavirus is, how it spreads, and what we know and don't know with Dr Jason Kindrachuk, Assistant Professor in the Department of Medical Microbiology and infectious diseases at the University of Manitoba. And...
Now Playing: Radiolab

Dispatch 1: Numbers
In a recent Radiolab group huddle, with coronavirus unraveling around us, the team found themselves grappling with all the numbers connected to COVID-19. Our new found 6 foot bubbles of personal space. Three percent mortality rate (or 1, or 2, or 4). 7,000 cases (now, much much more). So in the wake of that meeting, we reflect on the onslaught of numbers - what they reveal, and what they hide.  Support Radiolab today at Radiolab.org/donate.